SCHEMBL5362145

SCHEMBL5362145

N=C(N)Nc1ccc2c(c1)C(=Cc1ccc[nH]1)C(=O)N2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 6/20 0.81
AKT2 P31751 1/20 0.81
PDK1 Q15118 1/20 0.81
TLK2 Q86UE8 6/20 0.70
JAK3 P52333 1/20 0.70
CDK1 P06493 1/20 0.70
CCNB1 P14635 1/20 0.70
NEK2 P51955 1/20 0.70
NTRK1 P04629 2/20 0.67
PDGFRB P09619 4/20 0.65
HDAC3 O15379 4/20 0.65
HDAC1 Q13547 4/20 0.65
HDAC2 Q92769 4/20 0.65
FLT1 P17948 3/20 0.65
KDR P35968 3/20 0.65
HDAC6 Q9UBN7 3/20 0.65
HDAC4 P56524 2/20 0.65
HDAC7 Q8WUI4 2/20 0.65
HDAC10 Q969S8 2/20 0.65
HDAC11 Q96DB2 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29770021 0.90 PDPK1 (1.00) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5728134 0.90 PDPK1 (1.00) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5728132 0.90 PDPK1 (1.00) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5851570 0.86 PDPK1 (0.84) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5851557 0.86 PDPK1 (0.84) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5727583 0.85 PDPK1 (1.00) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5727586 0.85 PDPK1 (1.00) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5366002 0.82 PDPK1 (0.80) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5728368 0.82 PDPK1 (0.74) PDPK1AKT2PDK1TLK2JAK3
SCHEMBL5728365 0.82 PDPK1 (0.74) PDPK1AKT2PDK1TLK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDPK1 31/4885AKT2 450/4885PDK1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.